The Charles Bonnet Syndrome Market, characterized by the provision of diagnostic and therapeutic solutions for visually-impaired individuals experiencing complex visual hallucinations, is poised for significant expansion. This growth is fundamentally driven by the rising global prevalence of age-related macular degeneration (AMD), glaucoma, and other sight-loss conditions, particularly...